Difference between revisions of "Non-small cell lung cancer - historical"
(Created page with "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span s...") |
m |
||
Line 19: | Line 19: | ||
=Advanced or metastatic disease, first-line= | =Advanced or metastatic disease, first-line= | ||
+ | ==Best supportive care== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | !Study | ||
+ | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !Comparator | ||
+ | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[http://ascopubs.org/doi/abs/10.1200/JCO.1999.17.10.3188 Cullen et al. 1999 (MIC2)] | ||
+ | |style="background-color:#1a9851"|Phase III | ||
+ | |[[#MIC|MIC]] | ||
+ | |style="background-color:#fc8d59"|Seems to have inferior OS | ||
+ | |- | ||
+ | |} | ||
+ | ''No active antineoplastic treatment.'' | ||
+ | |||
+ | ===References=== | ||
+ | # Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188-94. [http://ascopubs.org/doi/abs/10.1200/JCO.1999.17.10.3188 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10506617 PubMed] | ||
+ | |||
+ | ==MACC {{#subobject:3f2f0c|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | MACC: '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>C</u>'''CNU (Lomustine) | ||
+ | ===Regimen {{#subobject:cec9d6|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | !Study | ||
+ | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !Comparator | ||
+ | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19820901)50:5%3C845::AID-CNCR2820500507%3E3.0.CO;2-S/abstract Cormier et al. 1982] | ||
+ | |style="background-color:#1a9851"|Phase III | ||
+ | |[[#Placebo|Placebo]] | ||
+ | |style="background-color:#1a9850"|Superior OS | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Methotrexate (MTX)]] | ||
+ | *[[Doxorubicin (Adriamycin)]] | ||
+ | *[[Cyclophosphamide (Cytoxan)]] | ||
+ | *[[Lomustine (Ceenu)]] | ||
+ | ===References=== | ||
+ | # Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845-9. [http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19820901)50:5%3C845::AID-CNCR2820500507%3E3.0.CO;2-S/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7093924 PubMed] | ||
+ | |||
==MIC {{#subobject:d1b4dd|Regimen=1}}== | ==MIC {{#subobject:d1b4dd|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 24: | Line 74: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | MIC: '''<u>M</u>''' | + | MIC: '''<u>M</u>'''itomycin, '''<u>I</u>'''fosfamide, '''<u>C</u>'''isplatin |
===Regimen {{#subobject:99a9f2|Variant=1}}=== | ===Regimen {{#subobject:99a9f2|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
Line 31: | Line 81: | ||
!Comparator | !Comparator | ||
![[Levels_of_Evidence#Efficacy|Efficacy]] | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[http://ascopubs.org/doi/abs/10.1200/JCO.1999.17.10.3188 Cullen et al. 1999 (MIC2)] | ||
+ | |style="background-color:#1a9851"|Phase III | ||
+ | |[[#Best_supportive_care|Best supportive care]] | ||
+ | |style="background-color:#91cf60"|Seems to have superior OS | ||
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract Danson et al. 2003] | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract Danson et al. 2003] | ||
Line 49: | Line 104: | ||
===References=== | ===References=== | ||
+ | # Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188-94. [http://ascopubs.org/doi/abs/10.1200/JCO.1999.17.10.3188 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10506617 PubMed] | ||
# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12879472 PubMed] | # Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12879472 PubMed] | ||
# Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://academic.oup.com/annonc/article/17/7/1111/212924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16603599 PubMed] | # Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://academic.oup.com/annonc/article/17/7/1111/212924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16603599 PubMed] | ||
Line 84: | Line 140: | ||
# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12879472 PubMed] | # Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12879472 PubMed] | ||
# Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://academic.oup.com/annonc/article/17/7/1111/212924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16603599 PubMed] | # Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://academic.oup.com/annonc/article/17/7/1111/212924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16603599 PubMed] | ||
+ | |||
+ | ==Placebo== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | !Study | ||
+ | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !Comparator | ||
+ | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19820901)50:5%3C845::AID-CNCR2820500507%3E3.0.CO;2-S/abstract Cormier et al. 1982] | ||
+ | |style="background-color:#1a9851"|Phase III | ||
+ | |[[#MACC|MACC]] | ||
+ | |style="background-color:#d73027"|Inferior OS | ||
+ | |- | ||
+ | |} | ||
+ | ''No active antineoplastic treatment.'' | ||
+ | |||
+ | ===References=== | ||
+ | # Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845-9. [http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19820901)50:5%3C845::AID-CNCR2820500507%3E3.0.CO;2-S/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7093924 PubMed] | ||
[[Category:Non-small cell lung cancer regimens]] | [[Category:Non-small cell lung cancer regimens]] |
Revision as of 05:11, 6 January 2018
Hello! |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main NSCLC page for current regimens.
30 regimens on this page
48 variants on this page
|
Advanced or metastatic disease, first-line
Best supportive care
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Cullen et al. 1999 (MIC2) | Phase III | MIC | Seems to have inferior OS |
No active antineoplastic treatment.
References
- Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188-94. link to original article PubMed
MACC
back to top |
MACC: Methotrexate, Adriamycin (Doxorubicin), Cyclophosphamide, CCNU (Lomustine)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Cormier et al. 1982 | Phase III | Placebo | Superior OS |
Chemotherapy
References
- Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845-9. link to original article PubMed
MIC
back to top |
MIC: Mitomycin, Ifosfamide, Cisplatin
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Cullen et al. 1999 (MIC2) | Phase III | Best supportive care | Seems to have superior OS |
Danson et al. 2003 | Phase III | GC | Seems not superior |
Booton et al. 2006 (BTOG1) | Phase III | DCb | Seems not superior |
Chemotherapy
References
- Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188-94. link to original article PubMed
- Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. link to original article PubMed
- Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. link to original article PubMed
MVP
back to top |
MVP: Mitomycin, Vinblastine, Platinol (Cisplatin)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Danson et al. 2003 | Phase III | GC | Seems not superior |
Booton et al. 2006 (BTOG1) | Phase III | DCb | Seems not superior |
Chemotherapy
References
- Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. link to original article PubMed
- Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. link to original article PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Cormier et al. 1982 | Phase III | MACC | Inferior OS |
No active antineoplastic treatment.
References
- Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845-9. link to original article PubMed